Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 598 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Complex Patients Clear all

Conditions: Health Services, Comorbidity, Primary Health Care
Interventions: SUMMIT intervention, Enhanced usual care; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cognition Disorders, HIV Infections
Interventions: Selegiline hydrochloride; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • Honolulu, Hawaii + 10 more

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Clarithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland

Conditions: Type 2 Diabetes, Healthy (Controls)
Interventions: Not applicable- observational study; Other
Lead sponsor: Guardian Research Network, Inc.; Other
Eligibility: 40 Years to 70 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Orangeburg, South Carolina • Walhalla, South Carolina

Conditions: Sarcoma
Interventions: vitespen; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: AS-101; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Clarithromycin, Rifabutin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 24 more

Conditions: HIV Infections, Cytopenias
Interventions: Filgrastim, Epoetin alfa, Zidovudine; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Serous Adenocarcinoma, Endometrioid Stromal Sarcoma, Recurrent Uterine Corpus Carcinoma
Interventions: Trebananib; Biological
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 33
States / cities: Hartford, Connecticut • New Britain, Connecticut • Sarasota, Florida + 23 more

Conditions: Pediatrics, Medically Complex, Children With Medical Complexity (CMC), Nursing
Interventions: CHAMP App; Device
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 0 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions: Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System; Drug · Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 18
States / cities: Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more

Conditions: Complex Regional Pain Syndrome (CRPS)
Interventions: transcranial alternating current stimulation (tACS); Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Adult Refractory Complex Partial Seizures
Interventions: Sabril; Drug
Lead sponsor: Lundbeck LLC; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 22
States / cities: San Francisco, California • New Haven, Connecticut • Dover, Delaware + 19 more

Conditions: Wounds and Injuries, Wound Infection, Facial Bones Fracture, Soft Tissue Injuries, Skull Fractures, Surgical Wound, Surgical Wound Infection, Wound Healing, Disturbance of Wound Healing, Wound; Head, Multiple, Wound; Head, Scalp, Wound; Head, Wound Complication, Wound Dehiscence, Wound of Skin, Wound Open, Wounds, Penetrating, Wounds, Nonpenetrating, Wounds
Interventions: Not listed
Lead sponsor: Dufresne, Craig, MD, PC; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Ventricular Tachycardia, Premature Ventricular Contraction, Stroke
Interventions: DOAC, Aspirin; Drug
Lead sponsor: Kansas City Heart Rhythm Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Kansas City, Kansas • Overland Park, Kansas • The Bronx, New York + 1 more

Conditions: Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2026
U.S. locations: 16
States / cities: San Diego, California • Stanford, California • Aurora, Colorado + 12 more

Conditions: HIV Infections
Interventions: Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 12
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 7 more

Conditions: HIV Infections
Interventions: Ritonavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 3
States / cities: Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio

Conditions: Blood Coagulation Disorders, Acute Major Bleeding
Interventions: Beriplex® P/N (Kcentra), Fresh frozen plasma; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • San Franciso, California + 33 more

Conditions: Kidney Cancer
Interventions: dactinomycin, filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2006
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Invasive Cryptococcosis
Interventions: ABLC; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Medically Complex Children, Care Coordination, Case Manager, Care Manager, Collaborative Care, Disease Management, Patient Care Team or Organization, Managed Care, Children With Chronic Conditions, Children With Special Health Care Needs, Shared Care Plan, Patient Care Plan, Health Care and Resource Utilization, Adherence to Care, Functional Status and Productivity, Health Related Quality of Life, Satisfaction With Care, Care Coordinator, Family Experience of Care, Quality Health Care
Interventions: Comprehensive Case Management Service; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 3 Months to 18 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: TSC1, TSC2, Tuberous Sclerosis Complex, MTOR
Interventions: Everolimus; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Search by objective public record fields.

Ambulatory ICU Study for Medically and Socially Complex Patients

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS

Specimen and Data Collection in South Carolina Medicaid-Enrolled Patients With Type 2 Diabetes (T2D) and Metabolically Healthy Controls

Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma

An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Parental Adherence of a Mobile Application

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

Effects of Non-invasive Brain Stimulation on Pain Avoidance Behavior in Chronic Pain Patients

A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds

DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation

North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors

An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2

Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex

Improving Care for Children With Complex Needs

Everolimus for Cancer With TSC1 or TSC2 Mutation